|Status : Published
|Published On : Dec, 2023
|Report Code : VRHC1259
|Industry : Healthcare
|Available Format :
|Page : 200
The Global Viral and Non-viral Vector Manufacturing Market is anticipated to grow from USD 1.6 billion in 2023 to USD 24.3 billion by 2030, registering a CAGR of 18.45% during the forecast period 2025-2030. Innovative therapies that involve vectors, such as gene therapy and cell therapy, have had a tremendous impact on medicine in the last few decades. Therapies that require genetic modification, such as the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, have shown significant impact in the treatment of a variety of fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, etc. The creation and standardization of numerous viral and non-viral vectors to meet unmet medical needs have been emphasized in light of the promising outcomes shown by these vector-based therapeutics in several preclinical and clinical investigations.
The viral and non-viral vector manufacturing market refers to the sector involved in the production of viral and non-viral vectors, which are essential tools in gene therapy and gene delivery applications. These vectors are used to transport therapeutic genes or genetic material into target cells to treat various genetic disorders, cancers, and other diseases. Viral Vector Manufacturing: Viral vectors are derived from viruses, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAV). They are modified to remove their disease-causing properties and engineered to deliver therapeutic genes to specific cells. Viral vector manufacturing involves the production, purification, and characterization of these vectors. It requires specialized facilities and expertise to ensure the safety, efficacy, and quality of the vectors.
The viral vector and non-viral manufacturing industries are projected to benefit from the COVID-19 epidemic. there are many COVID-19 vaccine candidates which have entered into clinical trials and including viral vector vaccines. These vaccines are very likely to be among the COVID-19 vaccines that have been approved for use worldwide.
Insight by Vector Type
Based on vector type, the global viral and non-viral vector manufacturing market is segmented into viral vector and non-viral vectors. The viral vector is further divided into Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vectors. The non-viral vector is further divided into Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vectors. Because of the ease of application in major target diseases such as cancer and genetic disorders, the retroviral vectors segment dominated the market.
Insight by Disease
Based on disease, the global viral and non-viral vector manufacturing market is classified into cancer, genetic disease, infectious disease, cardiovascular disease, and other diseases. The cancer segment is anticipated to contribute to the largest share during the forecast period owing to the rising number of clinical trials and availability of approved viral vector-based cancer drugs. Furthermore, the rising number of patients suffering from cancer and modern healthcare facilities will propel the growth of the market.
The genetic disorders segment is anticipated to grow at a faster pace during the forecast period owing to the rising number of research activities like hemophilia A & B, Huntington’s disease, sickle cell anemia, etc. and a robust genetic therapy pipeline will accelerate the growth of the market.
Insight by Application
Based on application, the global viral and non-viral vector manufacturing market is divided into gene therapy, vaccinology, cell therapy, and others. Gene therapy is anticipated to witness the largest share in the market owing to the rising number of gene therapy clinical trials for chronic and infectious diseases like cancer, cardiovascular diseases, and neurodegenerative diseases globally.
Global Viral and Non-Viral Vector Manufacturing Market Report Coverage
2018 - 2023
Base Year Considered
2025 - 2030
Market Size in 2023
U.S.D. 1.6 Billion
Revenue Forecast in 2030
U.S.D. 24.3 Billion
Segments Covered in the Report
By Vector Type, By Disease, and By Application
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report
North America, Europe, Asia-Pacific, Middle East, and Rest of the World
Non-Viral Vector Manufacturing: Non-viral vectors are typically synthetic or plasmid-based carriers that can deliver therapeutic genes into cells without the use of viruses. They are generally safer and less immunogenic than viral vectors but may have lower transfection efficiency. Non-viral vector manufacturing involves the production and formulation of these vectors, optimizing their delivery capabilities and ensuring their stability and functionality.
Growing Interest in Gene Therapy: Gene therapy holds tremendous potential for treating various genetic and acquired diseases. The increasing prevalence of genetic disorders and the need for more effective treatments have led to a surge in research and development activities in gene therapy, thereby driving the demand for viral and non-viral vectors.
Advancements in Vector Engineering: Significant advancements have been made in vector engineering, including the development of more efficient viral vectors with improved safety profiles and the design of non-viral vectors with enhanced transfection efficiency. These advancements have expanded the possibilities for gene therapy and increased the demand for vector manufacturing.
Increasing Clinical Trials and Approvals: The number of clinical trials involving gene therapy has been steadily increasing, with a growing number of therapies receiving regulatory approvals. This trend has resulted in a higher demand for viral and non-viral vectors to support these clinical trials and the commercial production of gene therapies.
Investment and Collaboration: Increased investments from biotechnology and pharmaceutical companies, as well as collaborations between academic institutions and industry players, have contributed to the growth of the viral and non-viral vector manufacturing market. These investments and collaborations aim to improve vector manufacturing processes, scale-up production, and accelerate the development of gene therapies.
The viral and non-viral vector manufacturing market is expected to experience significant growth in the coming years as gene therapy continues to evolve and gain traction as a promising treatment modality. Advances in vector engineering, manufacturing technologies, and regulatory frameworks will further drive the market, supporting the development and commercialization of innovative gene therapies.
The challenges faced by the viral and non-viral vector manufacturing market include massive cost involved in gene therapy, surging manufacturing cost of viral vectors, complications involved in large scale production of viral vectors along with low transfection efficiency for non-viral vectors might impede the growth of the market.
The rapid rise in genetically modified therapies, increased demand for synthetic genes along the advent of next-generation vectors has resulted in a significant increase in demand for various vectors for basic and pharmacological research, creating opportunities for companies with expertise in targeted gene delivery. Viral vectors and non-viral vectors have attracted substantial global attention as a potential therapeutic method to treat a wide variety of severe diseases, resulting in increased investments in drug research and commercialization. The global viral and non-viral vector manufacturing market is growing due to the increasing popularity of gene and cell therapy products (which use vectors), increased adoption of nucleic acid therapeutics in non-viral vectors, mounting synergistic activities, and increased funding activities supporting vector-based therapeutic research will bolster the growth of the market. Furthermore, rising rates of genetic abnormalities, cancer, and deadly diseases, as well as an expanding number of clinical trials and a solid pipeline of gene and cell therapy products along with vector-based vaccines, are all driving factors for market expansion.
North America contributes the largest share in the viral and non-viral vector manufacturing market owing to the increased implementation of viral vector-based gene therapies to treat chronic and rare diseases, rising number of regenerative medicine companies, availability of funds along with the availability of FDA approved gene therapies, thereby bolstering the growth in the region.
The global viral and non-viral vector manufacturing market is made up of both established and new companies. Several companies are attempting to enter the market and maintain competition by attempting to launch new manufacturing capacities, expanding their businesses, collaborating with viral and non-viral vector manufacturing companies to innovate new cell therapies, and vaccines for several diseases, or developing proprietary viral and non-viral vector platforms.
Catalent Cell & Gene Therapy is a technology, development, and manufacturing partner for breakthrough therapies that leads the industry. Its extensive cell therapy portfolio includes expertise in a wide range of cell types, which include CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines, with strong knowledge in viral vector discovery, scale-up, and production for gene treatments.
GenScript creates a GMP platform for vector production, including viral and non-viral vectors. Gene and cell therapy (GCT) has the potential to revolutionize medicine by offering long-term and perhaps curative treatment options for a variety of disorders. Plasmids and viruses in various quality levels are offered as part of the new medication development process to meet requirements at various stages with a quick turnaround time.
In October 2021, Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium, and Oxford Biomedica (OXB) stated that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners in order to advance and accelerate the development of a potential new treatment option for CF patients. In the partnership, IP Group grants exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis on behalf of the three GTC host universities. The GTC also contributes expertise in pre-clinical research and clinical gene therapy development. OXB is complementing Boehringer Ingelheim's expertise in the development of novel breakthrough therapies for respiratory diseases with its leading expertise in manufacturing lentiviral vector-based therapies.
In October 2021, Catalent, one of the prominent leaders in facilitating biopharma, cell, gene, and consumer health partners to significantly improve the development, launch, and supply of better patient treatments across multiple modalities, has announced a $230 million expansion project at its gene therapy campus in Harmans, Maryland, resulting in adding three more commercial-scale viral vector manufacturing suites, as well as associated support facilities and services, to meet growing customer demand.
Some of the industry players in the global viral and non-viral vector manufacturing market include Boehringer Ingelheim International GmbH, Catalent, Inc, GenScript ProBio, Lonza, Merck KGaA, Oxford Biomedica, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., and Evonik Industries AG.
The Viral and Non-Viral Vector Manufacturing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2023–2030.
Segments Covered in the Report
Region Covered in the Report
To explore more about this report - Request a free sample copy